Contraindicated (one)bortezomib will enhance the level or outcome of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Potent or moderate CYP2C19 inhibitors could maximize mavacamten systemic publicity, causing coronary heart failure because of systolic dysfunction. Drug Formulary information and facts is intended for use by Health care experts. It isn't https://franciszekh555vgs8.webbuzzfeed.com/profile